Plasma markers for identifying patients with metastatic melanoma.
about
A four-marker signature of TNF-RII, TGF-α, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanomaBeyond the zebrafish: diverse fish species for modeling human diseaseCEACAM1: Expression and Role in Melanocyte TransformationWhole Body Melanoma Transcriptome Response in MedakaTIMP-1 induces an EMT-like phenotypic conversion in MDCK cells independent of its MMP-inhibitory domain.Evaluating biomarkers in melanoma.Morphological effects on expression of growth differentiation factor 15 (GDF15), a marker of metastasis.Organ Specific Tumor Markers: What's New?Serum markers in early-stage and locally advanced melanoma.Serum CEACAM1 Elevation Correlates with Melanoma Progression and Failure to Respond to Adoptive Cell Transfer Immunotherapy.Variations in the expression of TIMP1, TIMP2 and TIMP3 in cutaneous melanoma with regression and their possible function as prognostic predictors.Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancerDiagnostic SOX10 gene signatures in salivary adenoid cystic and breast basal-like carcinomas.Prognostic value of the S100B protein in newly diagnosed and recurrent glioma patients: a serial analysis.Plasma osteopontin concentrations in patients with cutaneous melanomaConcise review: growth differentiation factor 15 in pathology: a clinical role?Combining multiple serum biomarkers in tumor diagnosis: A clinical assessment.TIMP-1 and CD82, a promising combined evaluation marker for PDAC.Microenvironment and tumor progression of melanoma: new therapeutic prospectives.Protein and non-protein biomarkers in melanoma: a critical update.Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis.Cytokine functions of TIMP-1.The divergent roles of growth differentiation factor-15 (GDF-15) in benign and malignant skin pathologies.Osteopontin has a protective role in prostate tumor development in mice.Comparative studies of TIMP-1 immunohistochemistry, TIMP-1 FISH analysis and plasma TIMP-1 in glioblastoma patients.Timp1 interacts with beta-1 integrin and CD63 along melanoma genesis and confers anoikis resistance by activating PI3-K signaling pathway independently of Akt phosphorylationBioinformatic Analysis of Gene Expression for Melanoma Treatment.The role of osteopontin expression in melanoma progression.CEACAM1 as a multi-purpose target for cancer immunotherapy.Elevated TIMP-1 expression is associated with a prometastatic phenotype, disease relapse, and poor survival in neuroblastoma.Bidirectional cross talk between patient-derived melanoma and cancer-associated fibroblasts promotes invasion and proliferation.Indoleamine 2,3 dioxygenase as a prognostic and follow-up marker in melanoma. A comparative study with LDH and S100B.An exploratory study investigating the metabolic activity and local cytokine profile in patients with melanoma treated with pazopanib and paclitaxel.Anorectal mucosal melanoma.
P2860
Q21245488-3DB3C460-9CA9-46AA-A085-45A83849ED17Q26853001-62B4704D-7476-4EDD-957F-4DE4E5893B23Q28072724-BF53BE67-092A-41CB-8864-B9959C15CFE0Q28551986-16A8B058-833F-42EB-9F2B-A3C527AC8CFDQ34305749-E234BF85-F250-4C98-97B0-A169444F4971Q35005677-7E9A4F98-F857-432F-93D6-EB2939DEE72BQ35821663-DD5F8701-D685-4BA2-B208-8CACB7C8FFCEQ35980584-65D696E2-DC4F-4762-AF13-7FD704662419Q36352802-231F11E4-B8AC-470D-9BDC-72CC57327851Q36356547-DFD87FCA-957E-4A5E-BF3B-9FC9AB604464Q36825423-192B2CBB-4031-48E6-AAED-3C3D6AE86A6FQ36853817-0FF5CD6D-3CDA-4291-8D32-E2BDC6E74211Q37040627-C05ADB4A-CD4C-4B4B-AD80-D481D2B00A77Q37250446-DA49CFD1-99CF-47D3-A373-8EDFF114B9A0Q37260595-1CB5EAEE-A8C9-4FE1-B5C1-A1085CDF7CEAQ37344271-E5ABDF9D-1FFE-4D29-BBD1-1CD805231B53Q37641050-44C2D84B-EECF-4AA6-8CFB-FC058EEEF479Q37701628-84DCB47F-9A9E-4E2A-8312-C60C512E331CQ38049368-E53D9D5F-E7DE-4B7D-BAE7-58E02D678F8BQ38050990-58C830B1-0351-4571-9329-10C49E22A32CQ38125604-B99C1AF4-7399-4206-8663-EFF53C22D802Q38132068-53D08922-BEE1-4ED2-A556-DC19725423B3Q38358925-6882583A-5ECF-42D2-A8B9-8CC270FA9B35Q38733548-ADBC235B-0E75-46C1-8BFB-033EB82D3262Q38822034-EFA2B27A-BA29-43E1-A42A-0930CF7EDC75Q39177033-19929BC8-DC67-43DA-8AE6-6436B44F6BB9Q40887187-1FB0A677-6780-4A35-81E1-92AE38849148Q40973252-C0C4D532-1E92-4DD8-B8B5-A221CBFCB31CQ41251368-5AB04E7B-81EA-4914-97E0-ADF3F4478523Q45645069-C2621E7E-EFB5-4F71-B5D9-088E568A0E76Q51220154-CFAB14DC-7EFB-4F20-A75C-3C61DC59AC29Q51502194-EAD86060-DB78-42DC-BFAC-AACE0C2B4AA9Q51746622-082CB865-A3BE-4105-BBCF-E6C020FCE186Q52680468-FF0541B2-F1F2-40FB-95FC-7C1CB4FB4FC7
P2860
Plasma markers for identifying patients with metastatic melanoma.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Plasma markers for identifying patients with metastatic melanoma.
@ast
Plasma markers for identifying patients with metastatic melanoma.
@en
type
label
Plasma markers for identifying patients with metastatic melanoma.
@ast
Plasma markers for identifying patients with metastatic melanoma.
@en
prefLabel
Plasma markers for identifying patients with metastatic melanoma.
@ast
Plasma markers for identifying patients with metastatic melanoma.
@en
P2093
P2860
P1476
Plasma markers for identifying patients with metastatic melanoma.
@en
P2093
Annette Molinaro
Harriet M Kluger
Jonathan Kirsch
Kathleen Hoyt
Ruth Halaban
Stephan Ariyan
Tina Mayer
Yuval Kluger
P2860
P304
P356
10.1158/1078-0432.CCR-10-2402
P407
P577
2011-04-12T00:00:00Z